The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77

Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol (2005) 1.49

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2005) 1.40

MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer (1998) 1.30

Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol (2010) 1.26

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15

Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis (2013) 1.13

Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol (2003) 1.12

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev (2012) 1.11

Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer (1999) 1.05

Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? Eur Radiol (2008) 0.94

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol (2009) 0.92

Practical considerations in ovarian cancer chemotherapy. Ther Adv Med Oncol (2010) 0.91

Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res (2010) 0.91

Epithelial ovarian cancer: An overview. World J Transl Med (2014) 0.91

Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87

Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol (2014) 0.85

Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev (2013) 0.84

Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep (2015) 0.83

The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma. World J Surg (2011) 0.82

Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol (2010) 0.82

Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82

Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.81

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study. Indian J Med Paediatr Oncol (2015) 0.80

The if and when of surgical debulking for ovarian carcinoma. N Engl J Med (2004) 0.80

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis. Sci Rep (2016) 0.79

Image guided biopsy in the management of cancer of the ovary. Cancer Imaging (2006) 0.79

Clinical utility of image-guided peritoneal and omental biopsy. Nat Rev Clin Oncol (2010) 0.78

Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008. Obstet Gynecol (2016) 0.78

Role of primary surgery in advanced ovarian cancer. World J Surg Oncol (2004) 0.78

Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer. Oncotarget (2016) 0.77

Interval cytoreduction in ovarian cancer. N Engl J Med (1995) 0.77

Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer (2013) 0.77

Interval debulking of ovarian cancer--an interim measure. N Engl J Med (1995) 0.77

Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively? World J Surg Oncol (2010) 0.76

A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol (2004) 0.76

Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery. J Gynecol Oncol (2011) 0.76

Interval cytoreduction in ovarian cancer. N Engl J Med (1995) 0.75

When should surgical cytoreduction in advanced ovarian cancer take place? J Oncol (2009) 0.75

Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. Int J Mol Sci (2017) 0.75

Changing Practice of Gynecologic Oncology based on Current Evidence. Med J Armed Forces India (2011) 0.75

Cytoreductive surgery in ovarian cancer. Cancer Imaging (2007) 0.75

Gynaecological cancer. Postgrad Med J (1999) 0.75

Interval cytoreduction in ovarian cancer. N Engl J Med (1995) 0.75

Management of asymptomatic primary tumours in stage IV colorectal cancer: Review of outcomes. World J Gastrointest Oncol (2015) 0.75

Management of gynaecological cancers. Qual Health Care (1999) 0.75

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. Oncologist (2016) 0.75

Recent EORTC and MRC UK studies: implications for imaging ovarian cancer. Cancer Imaging (2010) 0.75

Ovarian cancer (advanced). BMJ Clin Evid (2009) 0.75

Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. Int J Mol Sci (2017) 0.75

Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy. Oncol Lett (2017) 0.75

Double Pathology: Malignant Epithelial Ovarian Tumor and Germ Cell Tumor (Choriocarcinoma), a Rare Coexistence. World J Oncol (2015) 0.75

The miR-200 family in ovarian cancer. Oncotarget (2017) 0.75

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet (2000) 6.88

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76

Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol (2000) 4.25

Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med (1998) 3.98

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 3.25

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol (1991) 3.25

Center for Birth Defects Information Services. Birth Defects Orig Artic Ser (1980) 3.09

Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst (1989) 2.58

Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 2.47

Leptin secretion and leptin receptor in the human stomach. Gut (2000) 2.46

Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol (1994) 2.38

FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet (1999) 2.36

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19

Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain (2002) 2.17

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer (2008) 2.07

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol (2001) 2.03

Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood (1996) 2.01

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol (2002) 2.00

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 1.88

Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg (1988) 1.87

Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84

Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab (2012) 1.78

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet (1984) 1.77

Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes. Brain (2004) 1.73

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer (2006) 1.70

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70

Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces. Appl Environ Microbiol (2001) 1.69

Thalassemia intermedia and recurrent priapism following splenectomy. Haematologica (1991) 1.64

Production of methanethiol from methionine by Brevibacterium linens CNRZ 918. J Gen Microbiol (1985) 1.63

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer (2011) 1.57

Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol (2009) 1.54

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol (1995) 1.54

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol (2006) 1.54

Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 1.54

Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (1994) 1.52

Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol (2003) 1.52

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol (1991) 1.49

Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: a report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapy. Cancer (1998) 1.49

The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials (1997) 1.49

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol (2001) 1.45

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44

Carcinoma of the corpus uteri. J Epidemiol Biostat (2001) 1.42

Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid. Acta Neurol Scand (1990) 1.41

The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg (1987) 1.40

Pupillary enlargement caused by an acute extradural haematoma associated with a non-symptomatic arachnoid cyst, from compression of the optic rather than the oculomotor nerve. Br J Neurosurg (1999) 1.39

Hormone replacement therapy in breast cancer. Lancet (1993) 1.39

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol (2010) 1.39

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer (2005) 1.39

Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer. Bone Marrow Transplant (2004) 1.37

Carcinoma of the ovary. Int J Gynaecol Obstet (2003) 1.36

In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI). Lancet (1996) 1.35

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol (1987) 1.34

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]. Therapie (2000) 1.34

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33

Biochemical and genetic characterization of PepF, an oligopeptidase from Lactococcus lactis. J Biol Chem (1994) 1.32

Cancer in women. Int J Gynaecol Obstet (2003) 1.31

Surgical treatment of drug-resistant nocturnal frontal lobe epilepsy. Brain (2006) 1.31

Carcinoma of the corpus uteri. Int J Gynaecol Obstet (2003) 1.30

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol (2009) 1.29

Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med (1998) 1.28

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology (2003) 1.28

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27

Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol (1994) 1.26

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25

Should doctors reconstruct the vaginal introitus of adolescent girls to mimic the virginal state? Who wants the procedure and why. BMJ (1998) 1.25

Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol (2012) 1.23

Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet (2003) 1.23

Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab (2001) 1.23

Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts. Proc Natl Acad Sci U S A (1988) 1.23

Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol (1999) 1.21

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20

Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol (2006) 1.19

Anterior suspended flaps: a modified approach for external dacryocystorhinostomy. Br J Ophthalmol (1998) 1.19

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer (2011) 1.19

Carcinoma of the cervix uteri. J Epidemiol Biostat (2001) 1.19